Italy's Stevanato Q1 revenue rises more than expected, helped by GLP-1 demand

Stevanato SpA

07/05/2026 11:43

Overview

Italy drug delivery solutions firm's Q1 revenue rose 7%, beating analyst expectations

Adjusted EPS for Q1 beat consensus

Company maintained fiscal 2026 guidance

Outlook

Stevanato maintains fiscal 2026 guidance for revenue at €1.26 bln to €1.29 bln

Company expects adjusted EBITDA for 2026 between €331.8 mln and €346.9 mln

Stevanato expects adjusted diluted EPS for 2026 in the range of €0.59 to €0.63

Result Drivers

BDS SEGMENT GROWTH - 13% revenue increase in Biopharmaceutical and Diagnostic Solutions segment offset Engineering segment decline

HIGH-VALUE SOLUTIONS - Revenue from high-value solutions rose 17%, led by high-performance syringes and EZ-fill vials

BIOLOGICS AND GLP-1 DEMAND - Biologics revenue grew 15%, driven by GLP-1 treatments accounting for 21-22% of total revenue

Company press release: ID:nBw69qVpTa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
EUR 273.60 mln
EUR 269.35 mln (8 Analysts)
Q1 Adjusted EPS
Beat
EUR 0.11
EUR 0.10 (9 Analysts)
Q1 EPS
EUR 0.10
Q1 Net Income
EUR 28 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)